Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...
Clinical Trials Arena on MSN13d
Avidity’s del-zota elicits 25% increase in dystrophin in DMD patientsThe company plans to submit a Biologics Licence Application to the US Food and Drug Administration later in 2025 for its DMD ...
Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...
Results from the company’s Explore44 trial (NCT05670730) found that targeted delivery of del-zota, an antibody oligonucleotide conjugate (AOC), saw an approximate increase of 40% in exon 44 ...
Avidity Biosciences, Inc.'s innovative AOC platform and promising clinical programs make it a high-risk, high-reward ...
Del-zota produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44, a Phase 1/2 study in patients with DMD44 (oral presentation) Aravindhan Veerapandiyan ...
Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital and EXPLORE44 ® trial investigator, will present ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback